Interest in the p38 family has been particularly intense following the discovery that p38 MAPK inhibitors have an anti-inflammatory effect in models of arthritis and inflammatory angiogenesis in vivo, suppressing the expression of inflammatory cytokines, including interlekin-8 (IL-8), TNF-α, and MMPs [28-30]. The gene discussed is CXCL8; the disease is Arthritis.